



## **Osteosarcoma: Current Advances from Molecular and Cellular Mechanisms to Therapy**

Guest Editors:

**Dr. Virinder Kaur Sarhadi**

Department of Oral and  
Maxillofacial Diseases, Helsinki  
University Hospital and  
University of Helsinki, 00290  
Helsinki, Finland

**Dr. Francesca Perut**

Biomedical Science and  
Technologies and  
Nanobiotechnology Lab, IRCCS  
Istituto Ortopedico Rizzoli, Via di  
Barbiano 1/10, 40136 Bologna,  
Italy

Deadline for manuscript  
submissions:

**closed (20 January 2025)**

### **Message from the Guest Editors**

Osteosarcoma is a rare aggressive primary bone cancer. The tumors are highly heterogeneous with complex genomic landscape involving numerous structural and copy number alterations. Alterations in *TP53* are the most frequently somatic changes, while pathogenic germline mutations in *RB1*, *TP53*, *RECQL4*, *BLM*, and *WRN* are associated with an increased risk of osteosarcoma. Tumor heterogeneity and a lack of recurrent driver mutations make it difficult to identify effective molecularly targeted therapies. Recent multi-omics studies have enhanced our understanding of the molecular pathways in osteosarcoma pathogenesis and are opening up new opportunities for biomarker-driven precision therapies based on molecular subtypes or altered genomic or cellular pathways such as PI3K-ATK-mTOR signaling, homologous recombination repair pathway, or therapies based on the immune profile/response of tumors. This Issue will compile recent research on various cellular and molecular processes involved in osteosarcoma growth, progression, and drug sensitivity/resistance, which could lead to the identification of new drug targets and improvements in osteosarcoma treatment.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. José L. Quiles

Department of Physiology,  
Institute of Nutrition and Food  
Technology “Jose Mataix”,  
Biomedical Research Center,  
University of Granada, Avda.  
Conocimiento s/n, 18100 Armilla,  
Granada, Spain

## Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

## Contact Us

---

*International Journal of Molecular  
Sciences* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/ijms  
ijms@mdpi.com  
X@IJMS\_MDPI